Complete regression induced by sorafenib of locally advanced HCC allowing curative resection

被引:63
作者
Irtan, Sabine [1 ]
Chopin-Laly, Xavier [1 ]
Ronot, Maxime [2 ]
Faivre, Sandrine [3 ]
Paradis, Valerie [4 ]
Belghiti, Jacques [1 ]
机构
[1] Univ Paris, AP HP, Dept HBP Surg, F-75252 Paris, France
[2] Univ Paris, AP HP, Dept Radiol, F-75252 Paris, France
[3] Univ Paris 07, AP HP, Dept Oncol, Paris, France
[4] Univ Paris, Beaujon Hosp, AP HP, Dept Pathol, F-75252 Paris, France
关键词
HCC; portal vein thrombosis; revascularization; sorafenib; treatment; ADVANCED HEPATOCELLULAR-CARCINOMA; REMISSION;
D O I
10.1111/j.1478-3231.2010.02441.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We report two cases of locally advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis (PVTT) who complete regression by sorafenib treatment allowed curative resection. Two male adult (59 and 57 years) cirrhotic patients with HCC associated with PVTT including one with lymph node involvement had elevated a-fetoprotein level (AFP) (867 and 17 000) and were treated with standard sorafenib treatment during 10 and 12 months respectively. Size decrease of the main tumour, disappearance of PVTT and normalization of AFP allowed curative surgical resection. No viable tumour cells were found in the specimen and the two patients are currently alive without recurrence 12 and 16 months after surgery. These first two cases of complete tumour necrosis after sorafenib treatment allow us to reconsider surgical treatment in patients with unresectable HCC responding to this medical treatment.
引用
收藏
页码:740 / 743
页数:4
相关论文
共 8 条
[1]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[2]   Sorafenib A Review of its Use in Advanced Hepatocellular Carcinoma [J].
Keating, Gillian M. ;
Santoro, Armando .
DRUGS, 2009, 69 (02) :223-240
[3]  
Leung TWT, 1999, CLIN CANCER RES, V5, P1676
[4]   Sorafenib in advanced hepatocellular carcinoma [J].
Llovet, Josep M. ;
Ricci, Sergio ;
Mazzaferro, Vincenzo ;
Hilgard, Philip ;
Gane, Edward ;
Blanc, Jean-Frederic ;
Cosme de Oliveira, Andre ;
Santoro, Armando ;
Raoul, Jean-Luc ;
Forner, Alejandro ;
Schwartz, Myron ;
Porta, Camillo ;
Zeuzem, Stefan ;
Bolondi, Luigi ;
Greten, Tim F. ;
Galle, Peter R. ;
Seitz, Jean-Francois ;
Borbath, Ivan ;
Haussinger, Dieter ;
Giannaris, Tom ;
Shan, Minghua ;
Moscovici, Marius ;
Voliotis, Dimitris ;
Bruix, Jordi .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :378-390
[5]   Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors [J].
Moore, M ;
Hirte, HW ;
Siu, L ;
Oza, A ;
Hotte, SJ ;
Petrenciuc, O ;
Cihon, F ;
Lathia, C ;
Schwartz, B .
ANNALS OF ONCOLOGY, 2005, 16 (10) :1688-1694
[6]   Portal Vein Tumor Thrombosis Revascularization During Sorafenib Treatment for Hepatocellular Carcinoma [J].
Novi, Marialuisa ;
Lauritano, Ernesto C. ;
Piscaglia, Anna C. ;
Barbaro, Brunella ;
Zocco, Maria A. ;
Pompili, Maurizio ;
Gasbarrini, Antonio .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (07) :1852-1854
[7]   Early Alpha-Fetoprotein Response Predicts Treatment Efficacy of Antiangiogenic Systemic Therapy in Patients With Advanced Hepatocellular Carcinoma [J].
Shao, Yu-Yun ;
Lin, Zhong-Zhe ;
Hsu, Chiun ;
Shen, Ying-Chun ;
Hsu, Chih-Hung ;
Cheng, Ann-Lii .
CANCER, 2010, 116 (19) :4590-4596
[8]   Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report [J].
Wang, Sean Xiang ;
Byrnes, Abigail ;
Verma, Sadhna ;
Pancoast, John R. ;
Rixe, Olivier .
TARGETED ONCOLOGY, 2010, 5 (01) :59-63